Survival Win With Inavolisib-Based Triplet in PIK3CA-Mutated Breast Cancer

Watchdoq May 22, 2025

(MedPage Today) -- CHICAGO -- Adding the PI3K-pathway inhibitor inavolisib (Itovebi) to palbociclib (Ibrance) and fulvestrant significantly improved survival in advanced breast cancer patients with PIK3CA-mutated, endocrine-resistant disease...

Read Full Article